drugset
drugset / Trial / NCT06615193

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

NCT06615193 ↗

Phase 1 Recruiting 111 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.

Timeline

Start
2024-08-12
Primary completion
2026-06-24
Completion
2028-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM2005 Unknown 0.3 mg/kg Intravenous
Subject HDM2005 Unknown 2.75 mg/kg Intravenous

Indications

cancer lymphoma